Your entry is only as good as your exit strategy...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AUGT...News....
Augme Technologies, Inc. Reports Third Quarter Revenue of $4.4 Million
8:02 AM ET 1/9/12 | Marketwire
Augme Technologies, Inc. (OTCBB: AUGT) ("Augme") ("the Company"), a technology and services leader in interactive media marketing that offers the only patented and innovative end-to-end mobile marketing platform, today announced its operating results for the third quarter and first nine months of fiscal 2012 ended November 30, 2011.
Third Quarter Highlights
View data
-- Revenue increased by approximately 244% over the second quarter. -- First full quarter of results from JAGTAG and Hipcricket, which the company acquired in July and August, 2011 respectively. -- SaaS revenue accounted for approximately 60% of total revenue. -- New order bookings (defined as the dollar value of contracts signed during the quarter) totaled $5.3 million. -- Backlog (defined as the dollar value of signed contracts including deferred revenue and unbilled revenue) was $13.1 million as of November 30, 2011. -- Completed $20.2 common stock offering. -- Two patents issued from USPTO to the Company.
"Augme's one-stop mobile marketing and mobile advertising services, now sold exclusively under the Hipcricket brand name, continued to gain traction among branded enterprises, retailers and agencies during the third quarter," said Paul Arena, Chief Executive Officer of Augme Technologies, Inc. "New business momentum has been growing and coupled with our 95% customer retention rate, resulted in new order bookings of $5.3 million, and quarter end backlog of over $13.0 million."
Mr. Arena continued, "As the shift of media dollars toward mobile channels continues to accelerate, we are focused on driving adoption of our AD LIFE(TM) end-to-end mobile marketing platform that is both supported by our patented technology and scalable. At the same time, we are pursuing an Enterprise OEM strategy to propel cost-efficient revenue generation. The combination of a hyper fast-growing mobile media market, a growth strategy backed by proven high-end capabilities for user engagements and a growing pipeline of contract opportunities gives us confidence that we are on the cusp of rapidly scaling revenue and will achieve cash flow break-even during fiscal 2013."
Third Quarter Financial Results
For the third fiscal quarter ended November 30, 2011, the Company reported revenue of $4,424,540, an increase of approximately 419%, compared to revenue of $853,169 for the third fiscal quarter ended November 30, 2010 and an increase of 244% compared to revenue of $1,287,122 for the second fiscal quarter ended August 31, 2011.
Software-as-a-Service (SaaS) license revenue accounted for 60% of third quarter revenue, Mobile Advertising Solutions accounted for 20% of quarterly revenue and Other revenue, which includes non-recurring revenue such as client development work and shorter term licenses, accounted for the remaining 20% of revenue.
Gross profit (revenues minus cost of revenues) increased 515% to $3,023,882, or 68% of revenue, for the third quarter of fiscal 2012, versus gross profit of $491,820, or 57.6% of revenue, for the third fiscal quarter ended November 30, 2010 and compared with $874,775, or 68.0% of revenue, for the second quarter of fiscal 2012. The increase in the gross margin represents the current mix of business and cost efficiencies.
Selling, general and administrative expenses increased 299% to $11,370,845 for the third quarter of fiscal 2012, versus SG&A expenses of $2,847,569 for the third quarter of fiscal 2011 ended November 30, 2010 and compared with $6,758,455 for the second quarter of fiscal 2012 ended August 31, 2011. The increase in operating expenses includes the added expenses of JAGTAG and Hipcricket and includes transition and consolidation expenses which are expected to taper off during the fourth fiscal quarter.
The Company recorded a net loss of $10,548,140, or $0.12 per share, for the third quarter of fiscal 2012, versus a net loss of $2,616,951, or $0.04 per share, for the third quarter of fiscal 2011 and compared to a net loss of $6,179,248, or $0.09 per share, for the second quarter of fiscal 2012. The net loss for the third quarter of 2012 included non-cash stock, option and warrant expense totaling $2,680,794, versus non-cash stock, option and warrant expense of $615,381 for the third quarter of fiscal 2011, and compared to non-cash stock, option and warrant expense of $2,032,954 for the second quarter of fiscal 2012.
Nine Month Financial Results
For the nine months ended November 30, 2011, the Company's revenue increased 272% to $6,917,448, versus $1,858,209 for the first nine months of the previous fiscal year. Gross profit increased 369% to $4,741,511 (69% of revenue) for the nine months ended November 30, 2011, versus $1,011,822 (54.5% of revenue) for the nine months ended November 30, 2010.
The Company recorded a net loss of $19,919,328 million, or $0.28 per share, for the first nine months of fiscal 2012, compared to a net loss of $9,265,483, or $0.16 per share, for the corresponding period of the previous fiscal year. The net loss for the first nine months of fiscal 2012 included non-cash stock, option and warrant expense totaling $5,531,334 million, compared to $4,990,281 for the first nine months of fiscal 2011. Depreciation and amortization expense was $1,789,776 for the first nine months of fiscal 2012 compared to $752,925. The increase is primarily a result of the amortization of intangibles related to the acquisitions or Hipcricket and JAGTAG.
Business Outlook
Management expects revenue for fiscal 2012 ending February 29, 2012 to be approximately $13.0 million and believes that the Company can achieve positive cash flow during fiscal 2013.
Additionally, the company expects to continue to report sequentially increased revenues with large enterprise customers going forward, as its leadership position within the mobile marketing industry has been solidified with the completed integration of JAGTAG and Hipcricket.
The Company's management remains confident in Augme's ability to monetize its intellectual property portfolio through litigation and licensing activities.
Conference Call Details
Management will host a conference call to discuss these results on Monday, January 9, 2012 at 11:00 a.m. EDT. To participate in the conference call, please call 866-625-0328 (domestic call-in) or 706-643-2088 (international call-in) and reference code # 38085625.
A live webcast of the conference call will be available in the corporate section of the company's website. All participants should call or access the website approximately 10 minutes before the conference begins.
A telephone replay of the conference call will be available from 2:00 p.m. EDT on January 9 until 11:59 p.m. EDT on January 16 by calling 855-859-2056 (domestic) or 404-537-3406 (international) and entering confirmation #38085625. An archived replay of the conference call will also be available in the corporate section of the company's website.
About Augme Technologies, Inc.
Augme Technologies, Inc. (OTCBB: AUGT) provides strategic services and mobile marketing technology to leading consumer and healthcare brands. Its platforms, including AD LIFE(TM), have provided measurable successes across an industry-leading 130,000+ campaigns for such clients as Macy's, MillerCoors, Nestle, KFC, and Clear Channel. Augme's offerings allow marketers, brands, and agencies the ability to plan, create, test, deploy, and track mobile marketing programs across every mobile channel, including SMS, 2D/QR codes, mobile websites, advertising networks, social media and branded apps. Augme's platforms facilitate consumer brand interaction and the ability to track and analyze campaign results. Using its own patented device-detection and proprietary mobile content adaptation software, AD LIFE(TM) solves the mobile marketing industry problem of disparate operating systems, device types, and on-screen mobile content rendering. Augme also provides business to consumer utilities including national mobile couponing solutions, strategic mobile healthcare tools, custom mobile application development, and consumer data tracking and analytics. In addition to AD LIFE(TM), Augme owns Hipcricket and licenses the digital broadcast platform BOOMBOX(R). Augme is headquartered in New York City, with operations in Seattle, Atlanta, Dallas, Los Angeles, San Francisco, Chicago, and Tucson. For more information, visit www.augme.com.
Augme Technologies, Inc.(TM), Augme(TM), AD LIFE(TM), BOOMBOX(R), AD SERVE(TM) and the Augme logo are trademarks of Augme Technologies, Inc. All rights reserved. 2009-11.
Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in Augme's Form 10-K for the year ended February 28, 2011 and more recent reports and registration statements filed with the SEC. Augme Technologies, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter such forward-looking statements, whether as a result of new information, future events or otherwise.
View data
AUGME TECHNOLOGIES, INC. CONSOLIDATED BALANCE SHEETS FOR THE PERIODS ENDED NOVEMBER 30, 2011 and FEBRUARY 28, 2011 (Unaudited) ASSETS November 30, February 28, 2011 2011 (as restated) --------------- --------------- Current Assets Cash and cash equivalents $ 16,947,363 $ 11,182,356 Accounts Receivable, net of allowance for doubtful accounts of $193,238 and $99,657, respectively 3,962,330 2,025,294 Prepaid Expenses and Other Current Assets 428,642 132,197 --------------- --------------- Total Current Assets 21,338,335 13,339,847 Property and equipment, net of accumulated depreciation of $1,253,963 and $1,058,728, respectively 333,437 570,964 Goodwill 47,484,708 13,106,969 Intangible assets, net of accumulated amortization of $3,709,002 and $2,134,501, respectively 38,542,339 4,945,545 Deposits 443,060 67,551 --------------- --------------- TOTAL ASSETS $ 108,141,879 $ 32,030,876 --------------- ---------------
View data
AUGME TECHNOLOGIES, INC. CONSOLIDATED BALANCE SHEETS FOR THE PERIOD ENDED NOVEMBER 30, 2011 and FEBRUARY 28, 2011 (Unaudited) LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) November, 30 February 28, 2011 2011 (as restated) ------------- ------------- Current Liabilities Accounts payable $ 4,081,304 $ 740,129 Deferred revenue, current 1,037,760 1,190,151 Acquisition related contingent Consideration 24,250,750 -0- ------------- ------------- Total current liabilities 29,369,814 1,930,280 Long-term Liabilities Accrued Liabilities 92,428 -0- ------------- ------------- Total liabilities 29,462,242 1,930,280 ------------- ------------- Stockholders' Equity (Deficit) Common stock, $.0001 par value; 250,000,000 shares authorized, 94,310,683 and 68,816,131 shares issued and outstanding, respectively 9,431 6,882 Additional paid-in capital 137,344,763 68,848,931 Accumulated deficit (58,674,557) (38,755,217) ------------- ------------- Total Stockholders' Equity 78,679,637 30,100,596 ------------- ------------- TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 108,141,879 $ 32,030,876 ------------- ------------- AUGME TECHNOLOGIES, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) For the For the Three Three Months Months Ended Ended November 30, November 30, 2011 2010 (as restated) ------------- ------------- REVENUE $ 4,424,540 $ 853,169 COST OF REVENUES 1,400,658 361,349 ------------- ------------- Gross Profit 3,023,882 491,820 OPERATING EXPENSES: Selling, general and administrative 11,370,845 2,847,569 Depreciation and amortization 1,236,520 261,209 Total Operating Expenses 12,607,365 3,108,778 ------------- ------------- LOSS FROM OPERATIONS (9,583,483) (2,616,958) OTHER EXPENSES Acquisition related contingent expense 966,750 -0- OTHER INCOME Interest income/(expense), net 2,093 7 NET LOSS (10,548,140) (2,616,951) ============= ============= BASIC AND DILUTED NET LOSS PER SHARE $ (0.12)$ (0.04) WEIGHTED AVERAGE SHARES OUTSTANDING Basic and diluted 84,758,161 60,412,028 AUGME TECHNOLOGIES, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) For the For the Nine Nine Months Months Ended Ended November 30, November 30, 2011 2010 (as restated) ------------- ------------- REVENUE $ 6,917,448 $ 1,858,209 COST OF REVENUES 2,175,937 846,387 ------------- ------------- Gross Profit 4,741,511 1,011,822 OPERATING EXPENSES: Selling, general and administrative 21,925,936 9,524,402 Depreciation and amortization 1,789,776 752,925 Total Operating Expenses 23,715,712 10,277,327 ------------- ------------- LOSS FROM OPERATIONS (18,974,201) (9,265,506) OTHER EXPENSES Acquisition related contingent expense 966,750 -0- OTHER INCOME Interest income/(expense), net 21,623 23 ------------- ------------- NET LOSS $ (19,919,328) $ (9,265,483) ============= ============= BASIC AND DILUTED NET LOSS PER SHARE: $ (0.28) $ (0.16) WEIGHTED AVERAGE SHARES OUTSTANDING Basic and diluted 70,422,761 58,549,934
View data
Contact: For Augme Technologies, Inc. Investor Relations Contact: Stephanie Prince / Jody Burfening Lippert/Heilshorn & Associates, Inc. (212) 838-3777 sprince@lhai.com or ir@augme.com Public Relations Contact: Ed Harrison fama PR (617) 986-5003 ed@famapr.com
SOURCE: Augme Technologies, Inc.
mailto:sprince@lhai.com
mailto:ir@augme.com
mailto:ed@famapr.com
ZLCS..News...Zalicus to Present at Biotech Showcase 2012 Conference
8:00 AM ET 1/4/12 | BusinessWire
Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that Mark H.N. Corrigan, MD, President and CEO is scheduled to present at the Biotech Showcase 2012 Conference at 2:00 p.m. PT on Tuesday, January 10, 2012, at the Parc 55 Wyndham, San Francisco. Interested parties may access a live webcast of the presentation by visiting the Zalicus website at www.zalicus.com. The webcast will be archived on the Zalicus website following the event.
About Zalicus
Zalicus Inc. (Nasdaq: ZLCS) is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. Zalicus applies its selective ion-channel modulation platform and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease. To learn more about Zalicus, please visit www.zalicus.com.
Forward-Looking Statement:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Zalicus, its product candidates, their potential and the plans for their clinical development, the Zalicus selective ion channel modulation technology, and related preclinical product candidates, Zalicus's combination drug discovery technology, cHTS, and its other business plans. These forward-looking statements about future expectations, plans, objectives and prospects of Zalicus may be identified by words like "believe," "expect," "may," "will," "should," "seek," "plan" or "could" and similar expressions and involve significant risks, uncertainties and assumptions, including risks related to the sale and marketing of Exalgo by Covidien, risks related to the development and regulatory approval of Zalicus's product candidates, including risks relating to formulation and clinical development of Synavive and Prednisporin, the unproven nature of the Zalicus drug discovery technologies, the ability of Covidien and Fovea/Sanofi Aventis to perform their obligations under their agreements with Zalicus, the ability of the Company or its collaboration partners to initiate and successfully complete clinical trials of its product candidates, the Company's ability to obtain additional financing or funding for its research and development and those other risks that can be found in the "Risk Factors" section of Zalicus's annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Zalicus periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Zalicus contemplated by these forward-looking statements. These forward-looking statements reflect management's current views and Zalicus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.
(c) 2012 Zalicus Inc. All rights reserved.
SOURCE: Zalicus Inc.
Zalicus Inc.
Justin Renz, CFO, 617-301-7575
JRenz@zalicus.com
or
Gina Nugent, 617-460-3579
gnugent@zalicus.com
RAM...watch for breakout of flag pattern to the upside...50 ma crossed 200 ma
SLTZ...News...Sunday afternoon pr....somebody wants a huge push for the open....
Solar Thin Films, Inc. in Talks with Large European Renewable Energy Developer
10:36 AM ET 1/8/12 | BusinessWire
Solar Thin Films, Inc. (Pinksheets:SLTZ) (the "Company") today announced that the Company is in talks with a large European renewable energy developer on several solar energy projects in Europe. The total output of such projects is anticipated to exceed 100 megawatts. There can be no assurance that any contracts will result from such talks, or that any contracts signed will have successful results.
Adiv Baruch, Chairman of the Board of the Cenergy Global Corp., a wholly-owned subsidiary of the Company, stated, "We are building a strong relationship with some of the leading players in the European market, who are experienced in developing profitable renewable energy projects. We are exposed to large size projects with unique economic parameters."
About Solar Thin Films, Inc.
Solar Thin Films, Inc. was formerly engaged in the manufacturing of solar module production equipment and turnkey amorphous silicon module factories. The Company has shifted its focus from turnkey facility production, to establishment, operation and management of solar farms domestically and internationally.
About Cenergy Global Corp.
Cenergy will seek to engage in the development and syndication of Solar Power projects. Forming Cenergy is the Company's latest step in shifting its focus to the establishment, operation and management of solar farms.
Forward-Looking Statements
This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Except as otherwise required by the federal securities laws, the Company disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein.
SOURCE: Solar Thin Films, Inc.
Creative Media
Donald R. D'Avanzo Jr., 1-888-699-7268
johnniemacusa@hotmail.com
O.T. Tebow Time...Yeah....Yeah...
SSN.. $2.42..break $2.50 and this goes...
LQMT...0.14... keep on watch...flag pattern...needs to break and hold 0.159....
OXGN...$1.04....watch for break of $1.14...20% of float is short...14 milion outstanding...
AUGT.. $1.47...upward reversal...breakout from flag pattern...
AQLV 0.O132.....http://www.aqualiv.com/experiments crazy stuff...
AQLV 0.O132...breakout of pennant to the upside..lots of room here...
BZH...$2.86...target $3.20 short term...riding the 200 ma...broke to the upside of an ascending triangle @ $2.60...higher lows and higher highs...insider buys in December in the $2.00 range..
CLSN...$1.92...33 million outstanding...keep on watch...nice move off the bottom...uptrend in motion...waiting to hold over $2.00...nice insider buying going on...
Latest news.....
Celsion Completes Consultative Review Process With EMA for Phase III HEAT Study of ThermoDox(R) in Primary Liver Cancer
9:51 AM ET 12/19/11 | Marketwire
Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced today that it has received written, scientific advice from the European Medicines Agency (EMA) confirming that the Company's Phase III HEAT Study, a multinational, double-blind, placebo controlled pivotal study of ThermoDox(R) in combination with radio frequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC), or primary liver cancer, is acceptable as a basis for submission of a marketing authorization application (MAA).
Based on feedback and guidance received from the EMA, the Company expects that future results demonstrating a convincing magnitude of improvement in progression-free survival, the study's primary endpoint, along with a favorable benefit-risk ratio in the HEAT Study, would be sufficient as the primary basis for registration of ThermoDox(R) in Europe. The EMA also supported the Company's manufacturing strategy and technology transfer protocols, which will allow the Company to establish multiple manufacturing sites to support commercialization of ThermoDox(R) outside the United States.
"We are delighted with the advice and feedback from the EMA as it provides Celsion with confirmation that our HEAT Study is well designed and will serve as a basis for ThermoDox(R) approval," said Michael H. Tardugno, Celsion's President and Chief Executive Officer. "Furthermore, we have a clear understanding on how best to design our nonclinical submission by following a similar course as our 505(b)(2) approach with the U.S. Food and Drug Administration. In addition to Orphan Drug Designation in Europe, received earlier this year, this positive outcome allows Celsion to move forward with a centralized filing in Europe and a clear regulatory pathway for product approval outside the U.S. A European approval provides the basis for international filings in countries that require an approval from a globally recognized regulatory agency."
In March of this year, Celsion announced that the European Commission granted orphan drug designation for ThermoDox(R) in primary liver cancer, which provides assistance and incentives, including 10 years of marketing exclusivity subsequent to product approval, in support of product candidates intended for the treatment of a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union. ThermoDox(R) also holds orphan drug designation in the U.S.
About Primary Liver Cancer
Primary liver cancer is one of the most deadly forms of cancer and ranks as the fifth most common solid tumor cancer. The incidence of primary liver cancer is approximately 26,000 cases per year in the United States, approximately 40,000 cases per year in Europe and is rapidly growing worldwide at approximately 700,000 cases per year, due to the high prevalence of Hepatitis B and C in developing countries. The standard first-line treatment for liver cancer is surgical resection of the tumor; however, 90% of patients are ineligible for surgery. Radio frequency ablation (RFA) has increasingly become the standard of care for non-resectable liver tumors, but the treatment becomes less effective for larger tumors. There are few non-surgical therapeutic treatment options available as radiation therapy and chemotherapy are largely ineffective in the treatment of primary liver cancer.
About ThermoDox(R) and the Phase III HEAT Study
ThermoDox(R) is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers. In the HEAT Study, ThermoDox(R) is administered intravenously in combination with RFA. Localized mild hyperthermia (39.5 - 42 degrees Celsius) created by the RFA releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor.
For primary liver cancer, ThermoDox(R) is being evaluated in a 700 patient global Phase III study at 76 clinical sites under an FDA Special Protocol Assessment. The study is designed to evaluate the efficacy of ThermoDox(R) in combination with Radio Frequency Ablation (RFA) when compared to patients who receive RFA alone as the control. The primary endpoint for the study is progression-free survival (PFS) with a secondary confirmatory endpoint of overall survival. Additional information on the Company's ThermoDox(R) clinical studies may be found at www.clinicaltrials.gov.
About Celsion Corporation
Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, and the North Shore Long Island Jewish Health System.
For more information on Celsion, visit our website: http://www.celsion.com.
Investor Contact
David Pitts
Argot Partners
212-600-1902
Email Contact
SOURCE: Celsion Corporation
http://www2.marketwire.com/mw/emailprcntct?id=93F06BF4C39D10BE
Enjoy...and have a great weekend....
ALTI... 0.65..nice bounce...got plenty left..
Nice...
MOTR....dips to low .80's I am a buyer...
XIDE...$3.16 X $3.17..taking a lunch break..looking for a break of $3.52 and then $3.83 with some volume..
MWWC..getting a little volume here...if puma would get off the ask for last 5 days maybe we could run....waiting for CC call next week according to the last PR....
VDSC...buying here..the dip is forming the handle for a cup that started forming in March2011..50 ma @ .12 which should hold and it should bounce to form the upward part of the handle...Target .35 if it breaks the resistance lid @ .20...we shall see...
Put ZOOM on your radar...moves real easy with volume...I have been accumulating from $1. it has been slowly moving up on no volume...when this has flown before it will get 350,000 by 10 A.M.
Signed a huge deal with China Mobile in late 2011..China Mobile approved their product line for distribution starting in the first quarter of 2012...China Mobile is the largest distributor in China.....nobody is talking about it...but I am betting it will be huge....any news at all will take this right thru $2.00 in a heartbeat..and to all time new highs...based on the deal with China Mobile coming to fruition.....you can see by the size of the upward candles that it has nice size moves...not 200% but better than Bank of America....
Low outstanding.... we shall see...
George
ENER..will get up on the 50ma or drop under the 20ma and flop...we shall see..
XIDE...$3.24 X $3.26
Beautiful....
Thank you....
Thanks mrgoodtrade....AEN...LEI...DEXO...are keepers.....
Beautiful Rig....
Post 197223...Jan 2...
LEI...$2.78
MTG...almost half of the float is short...large institutional buying...Kyle Bass in late 2011 purchased about 5% of the company.....this was $1.50 in Oct.2011...make your own conclusion but many folks got their butts handed to them on options in December...for playing the short side...YEAH...YEAH...
ALTI.. 0.629...
LQMT.... 0.14 X 0.145
DEXO..$2.40..
AEN...$1.67...this is a keeper folks...
ENER...trying to go green from nice dip...
ENER...nice dip here..
XIDE...$3.08 X $3.09
ARET...$2.00.. charts
SATM.. 0.029...charts...
Good bye 20's by 10 A.M. LOL.....